摘要
重度哮喘是哮喘患者致死和致残的主要因素,可造成巨大的社会和经济压力。近年来,随着对哮喘病理机制的深入了解,生物靶向治疗逐渐成为重度哮喘治疗的新选择。这些疗法通过精确抑制或调节炎症级联反应中的关键分子,从而有效缓解症状、改善肺功能,并降低急性发作的风险。它们标志着在重度哮喘治疗方面的范式转变。本文系统地探讨重度哮喘的免疫学特征,并对生物靶向治疗的现状和未来发展趋势进行全面评述,旨在为重度哮喘患者的个体化治疗提供科学、有益的参考依据。
Severe asthma stands as a formidable contributor to both mortality and morbidity of patients suffering asthma,casting substantial social and economic shadows on communities.As our understanding of asthma's pathophysiology deepens,a beacon of hope emerges in the form of biological targeted therapies,offering a promising avenue for the management of this challenging condition.These therapies,by precisely inhibiting or modulating pivotal molecules in the inflammatory cascade,offer potential benefits in symptom alleviation,lung function enhancement,and risk reduction of acute exacerbations.They signify a paradigm shift in severe asthma treatment.Within the confines of this article,we embark on a systematic exploration of the immunological underpinnings that define severe asthma.By delving into the intricacies of the immune system's role in exacerbating this condition,we aim to offer a comprehensive assessment of both the current landscape and the future prospects of biological therapies.Our objective is to provide a scientifically robust and valuable reference that can guide the individualized treatment of patients grappling with severe asthma.
作者
孙傲
王镜銮
刘文娟
任敦强
刘晓静
SUN Ao;WANG Jingluan;LIU Wenjuan;REN Dunqiang;LIU Xiaojing(Department of Respiratory and Critical Care Medicine,The Affiliated Hospital of Qingdao University,Qingdao 266000,Shandong,China;Community Health Service Center,Changjiang Road Sub-district,Huangdao District,Qingdao 266000,Shandong,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
北大核心
2024年第4期415-422,共8页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金青年项目(81300046)
青岛大学附属医院临床+X项目(3753)
青岛大学附属医院青年基金(3086)。
